Literature DB >> 10768556

Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers.

P D Mozley1, J S Schneider, P D Acton, K Plössl, M B Stern, A Siderowf, N A Leopold, P Y Li, A Alavi, H F Kung.   

Abstract

UNLABELLED: [99mTc]TRODAT-1 is a radiolabeled tropane that binds dopamine transporters. The primary goal of this study was to determine whether its regional cerebral distribution could differentiate between patients with Parkinson's disease and healthy human volunteers.
METHODS: The sample consisted of 42 patients with Parkinson's disease, 23 age-matched controls, and 38 healthy adults younger than 40 y old. SPECT scans of the brain were acquired on a triple-head gamma camera 3-4 h after the intravenous injection of 740 MBq (20 mCi) [99mTc]TRODAT-1. Mean counts per pixel were measured manually in subregions of the basal ganglia and normalized to the mean background counts to give specific uptake values ([SUVs] approximately k3/k4). Patient and control groups were also compared with automated statistical parametric mapping techniques. Logistic discriminant analyses were performed to determine the optimum uptake values for differentiating patients from age-matched controls.
RESULTS: Quantitative image analysis showed that the group mean SUVs in patients were less than the mean values in controls for all regions (all Ps < 0.000001). There was overlap in the caudate as well as in the anterior-most portion of the putamen, but not in the posterior putamen, even when the asymptomatic sides of 5 patients with clinically defined hemi-Parkinson's disease were factored in.
CONCLUSION: The findings indicate that Parkinson's disease can be detected with [99mTc]TRODAT by simply inspecting the images for uptake in the posterior putamen. Appropriate asymmetries seem to be visible with quantification in patients with clinically defined hemi-Parkinson's disease, even though changes in the putamen contralateral to the clinically unaffected side in these patients appear to precede the development of symptoms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768556

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  33 in total

1.  Association of the ZFPM2 gene with antipsychotic-induced parkinsonism in schizophrenia patients.

Authors:  Lior Greenbaum; Robert C Smith; Mordechai Lorberboym; Anna Alkelai; Polina Zozulinsky; Tzuri Lifschytz; Tzuri Lifshytz; Yoav Kohn; Ruth Djaldetti; Bernard Lerer
Journal:  Psychopharmacology (Berl)       Date:  2011-09-24       Impact factor: 4.530

Review 2.  Adaptive immune regulation of glial homeostasis as an immunization strategy for neurodegenerative diseases.

Authors:  Lisa M Kosloski; Duy M Ha; Jessica A L Hutter; David K Stone; Michael R Pichler; Ashley D Reynolds; Howard E Gendelman; R Lee Mosley
Journal:  J Neurochem       Date:  2010-05-26       Impact factor: 5.372

3.  Use of a single [123I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease.

Authors:  Ruth Djaldetti; Therese A Treves; Ilan Ziv; Eldad Melamed; Yair Lampl; Mordechai Lorberboym
Journal:  Neurol Sci       Date:  2009-06-05       Impact factor: 3.307

Review 4.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

5.  Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease.

Authors:  Yu Geng; Guo-hua Shi; Yun Jiang; Ling-xun Xu; Xing-yue Hu; Yu-quan Shao
Journal:  J Zhejiang Univ Sci B       Date:  2005-01       Impact factor: 3.066

6.  Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease.

Authors:  Randel L Swanson; Andrew B Newberg; Paul D Acton; Andrew Siderowf; Nancy Wintering; Abass Alavi; P David Mozley; Karl Plossl; Michelle Udeshi; Howard Hurtig
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

Review 7.  Preclinical diagnosis of Parkinson's disease: are we there yet?

Authors:  Andrew Siderowf; Matthew B Stern
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

8.  Dopamine transporter density of basal ganglia assessed with [123I]IPT SPET in obsessive-compulsive disorder.

Authors:  Chan-Hyung Kim; Min-Seong Koo; Keun-Ah Cheon; Young-Hoon Ryu; Jong-Doo Lee; Hong-Shick Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-25       Impact factor: 9.236

9.  Taste function in early stage treated and untreated Parkinson's disease.

Authors:  Richard L Doty; Michael T Nsoesie; Inna Chung; Allen Osman; Ian Pawasarat; Julie Caulfield; Howard Hurtig; Jonathan Silas; Jacob Dubroff; John E Duda; Gui-Shuang Ying; Hakan Tekeli; Fidias E Leon-Sarmiento
Journal:  J Neurol       Date:  2014-12-06       Impact factor: 4.849

10.  Iterative reconstruction with correction of the spatially variant fan-beam collimator response in neurotransmission SPET imaging.

Authors:  Deborah Pareto; Albert Cot; Javier Pavía; Carles Falcón; Ignacio Juvells; Francisco Lomeña; Domènec Ros
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-03       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.